KEYNOTE-811 Trial Shows Pembrolizumab Combination Improves Response Rates in HER2-Positive Gastric Cancer
Key Insights
The KEYNOTE-811 trial demonstrated significant improvement in objective response rate when pembrolizumab was added to trastuzumab and platinum-based chemotherapy for previously untreated HER2 (search)-positive gastric or gastroesophageal junction adenocarcinoma (search).
Updated analyses revealed progression-free survival advantage and continued durability of response, with greatest benefit observed in patients whose tumors express PD-L1 (search).
The safety profile of the pembrolizumab-containing regimen was consistent with expectations for PD-1 (search) inhibitors combined with HER2 (search)-targeted therapy and chemotherapy, with no new safety signals reported.
The KEYNOTE-811 randomized trial has demonstrated that adding pembrolizumab to standard trastuzumab and platinum-based chemotherapy significantly improves objective response rates in patients with previously untreated, HER2 (search)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. The study's primary early endpoint showed pembrolizumab led to higher rates of rapid and deep tumor responses compared with trastuzumab and chemotherapy alone.
Clinical Efficacy Results
The combination demonstrated a substantial improvement in objective response rate compared with trastuzumab and chemotherapy alone, which supported its accelerated regulatory approval. Updated analyses have shown a progression-free survival advantage and continued durability of response, with the greatest benefit observed among patients whose tumors express PD-L1 (search).
Exploratory analyses indicated that responses appear particularly strong in tumors expressing PD-L1 (search), suggesting potential biological synergy between HER2 (search)-targeted therapy and PD-1 (search) blockade. This finding points to the importance of biomarker-driven treatment selection in optimizing patient outcomes.
Safety Profile
The safety profile of the pembrolizumab-containing regimen was consistent with expectations for PD-1 (search) inhibitors in combination with HER2 (search)-targeted therapy and chemotherapy. No new safety signals were reported, and the regimen showed comparable rates of cardiac adverse events across treatment arms. No new or unexpected toxicities were observed during the trial.
Treatment Impact
KEYNOTE-811 has meaningfully influenced first-line treatment strategies for HER2 (search)-positive advanced gastric and GEJ cancers. The trial has played an important role in shaping current treatment strategies for patients with HER2-positive advanced gastric and GEJ cancers, providing a new therapeutic option that combines immunotherapy with established HER2-targeted treatment.
While overall survival results remain immature, the demonstrated improvements in response rates and progression-free survival, combined with the manageable safety profile, have established this combination as a significant advancement in the treatment of HER2 (search)-positive gastric and GEJ adenocarcinoma.